The application of toripalimab in the first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600117901

Enrollment

Unknown

Registered

2026-01-29

Start date

2025-01-27

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal carcinoma

Interventions

Observation Group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Voluntarily signed written informed consent; 2. Recurrent or metastatic nasopharyngeal carcinoma; 3. To be treated with a regimen containing toripalimab; 4. Locally advanced nasopharyngeal carcinoma with a high risk of recurrence or metastasis, voluntari using toripalimab during the treatment process.

Exclusion criteria

Exclusion criteria: 1. Known allergic to recombinant humanized anti-PD-1 monoclonal antibody drugs and their components; 2. The researchers determined that other conditions were not suitable for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
Progression-free survival;	—

Secondary

Measure	Time frame
Objective Response Rate;Disease control rate;Duration of relief;Overall survival;Safty;	—

Countries

China

Contacts

Public ContactXiaoshen Wang

Eye & ENT Hospital of Fudan University

ruijin702@163.com+86 180 1731 2704

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026